Projects

Projects per year 2006 2014 2018 2019 2020 2021 2024 2028

• 24 Active
• 39 Finished

Projects per year

Search results

• Active

  FWOSB171: Optimization of nanobodies targeting pannexin1 channels for the treatment of cholestasis.

  Peeters, D. & Vinken, M.

  1/11/24 → 31/10/28

  Project: Fundamental

• OZR4354: OZR opvangmandaat aspirant Annika Drees

  Vinken, M. & Drees, A. H.

  1/11/24 → 31/10/25

  Project: Fundamental

• FWOSB174: Development and testing of a new approach methodology for the prediction of human risk following exposure to mixtures of toxic chemicals

  Callewaert, E. & Vinken, M.

  1/11/24 → 31/10/28

  Project: Fundamental

• FWOTM1243: Testing of de novo generated nanobodies raised against connexin43 as novel therapeutics for the treatment of inflammatory liver disease

  Van Campenhout, R., Vinken, M., Devoogdt, N. & De Groof, T.

  1/10/24 → 30/09/27

  Project: Fundamental

• EUAR201: VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research

  Vinken, M.

  1/09/24 → 29/02/28

  Project: Applied

• ANI388: Next generation prediction of human safety of chemical compounds: liver toxicity as a case study

  Vinken, M.

  4/07/24 → 31/12/24

  Project: Fundamental

  • Chemical compounds 100%
  • Liver 57%
  • Toxicity 56%
  • Risk assessment 23%
  • Animals 23%

• FWOSB150: Role of cellular communication mediated by pannexin1 channels in non-alcoholic fatty liver disease induced by microgravity and radiation: testing of a pharmacological countermeasure for the protection of astronauts.

  Cools, B. & Vinken, M.

  1/11/23 → 31/10/27

  Project: Fundamental

  • Astronauts 100%
  • Weightlessness 93%
  • Non-alcoholic Fatty Liver Disease 78%
  • Radiation 54%
  • Communication 54%

• AIIFUND104: An animal-free approach for human safety testing of food additives

  Vinken, M.

  11/04/23 → 30/04/25

  Project: Fundamental

  • Food additives 100%
  • Safety testing 86%
  • food additives 63%
  • Animals 53%
  • liver 21%

• FWOAL1070: The role of pannexin1 channels in non-alcoholic steatohepatitis: therapeutic and diagnostic relevance.

  Vinken, M.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Fatty Liver 100%
  • Liver 82%
  • Adverse Outcome Pathways 77%
  • Single-Domain Antibodies 69%
  • acute course 67%

• AIIFUND87: Study Abroad Program Ministry of National Education - Turkey: Ph.D. Batuhan Yildiz

  Vinken, M. & Yildiz, B.

  1/02/22 → 31/12/25

  Project: Policy Based

  • RNA Sequencing 100%
  • Phalloidin 96%
  • Activation Analysis 81%
  • Apolipoprotein 73%
  • studies abroad 69%

• FWOAL1047: Can food additives cause liver damage? A mechanistic in vitro modelling study.

  Vinken, M.

  1/01/22 → 31/12/25

  Project: Fundamental

  • Adverse Outcome Pathways 100%
  • Liver 55%
  • Chemical and Drug Induced Liver Injury 39%
  • Parenteral 38%
  • mitochondria 38%

• OZR3923: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UGent, DE BOEVER Sybren

  Vinken, M.

  17/11/21 → 16/11/25

  Project: Fundamental

• OZR3898: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UGent, MAERTEN Amy

  Vinken, M.

  13/10/21 → 12/10/25

  Project: Fundamental

• OZRSRF43: Connexins, pannexins and their channels as drug targets and biomarkers of liver disease and toxicity

  Vinken, M.

  1/10/21 → 30/09/26

  Project: Fundamental

  • Biomarkers 100%
  • Toxicity 78%
  • Drugs 59%

• OZR3879: H2020: Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment (OZR EU BONUS)

  Vinken, M.

  1/05/21 → 30/04/26

  Project: Fundamental

  • Adverse Outcome Pathways 100%
  • Artificial Intelligence 87%
  • Fatty Liver 64%
  • toxicity testing 62%
  • risk assessment 62%

• EUAR61: H2020: Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment

  Vinken, M., Vanhaecke, T. & Rogiers, V.

  1/05/21 → 30/04/26

  Project: Fundamental

  • Adverse Outcome Pathways 100%
  • Cholestasis 72%
  • Machine Learning 67%
  • Risk Assessment 50%
  • Ecotoxicology 45%

• OZRMETH6: Cellular communication as target and biomarker in liver disease and toxicity: from basic research towards clinical application

  Vinken, M.

  1/01/21 → 31/12/27

  Project: Fundamental

  • Liver Diseases 100%
  • Budgets 67%
  • Biomarkers 57%
  • Connexins 46%
  • Liver 15%

• FWOWO39: Hepatic toxicity modeling and prediction: focus on drug-induced cholestasis

  Vinken, M.

  1/01/21 → 31/12/25

  Project: Fundamental

  • Toxicity 100%
  • credit 18%
  • drug 14%
  • Group 6%

• EU624: Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular and hepatic diseases

  Vinken, M. & Ballet, S.

  European Commission

  1/03/20 → 28/02/25

  Project: Fundamental

  • Connexins 100%
  • Budgets 91%
  • Cardiovascular Diseases 58%
  • Liver 41%
  • Antiinflammatory 38%

• IOF3013: GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.

  Vanhaecke, T., van Grunsven, L., De Kock, J., Vinken, M., Reynaert, H., Van der Eycken, W., Van Goethem, F. & Fernando, R.

  1/01/20 → 31/12/24

  Project: Applied

  • toxicology 100%
  • cell biology 91%
  • product safety 86%
  • hepatocytes 77%
  • liver 76%

• SRP50: SRP-Onderzoekszwaartepunt: Exploiting Peptides: Protein Binders, Modulators and Inhibitors for Imaging and Therapy [Exploit-PeptIT]

  Ballet, S., Caveliers, V., Hernot, S., Versées, W., Vinken, M., Muyldermans, S., Devoogdt, N., Bridoux, J. & Martin, C.

  1/03/19 → 30/09/25

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Neoplasms 14%
  • Radioisotopes 13%
  • Immunoglobulin Fragments 11%
  • Peptide 11%

• AIIFUND32: Repeated dose toxicity ontology project : Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study.

  Vinken, M.

  29/05/18 → …

  Project: Fundamental

  • Chemical Safety 100%
  • chemical risk 89%
  • Europa 82%
  • Connexins 78%
  • Gap Junctions 72%

• OZR2651: International Joint Research Group - Liver Connexin and Pannexin Research Group (LCPR)

  Vinken, M., Rogiers, V., Cogliati, B. & Dagli, M. L.

  1/08/14 → 1/07/26

  Project: Fundamental

  • Connexins 100%
  • Liver 67%
  • Acetaminophen 63%
  • Gap Junctions 47%
  • Liver Cirrhosis 39%

• OZR2275: Connexin and pannexin channels: function, regulation and applications

  Vinken, M. & Leybaert, L.

  1/09/11 → …

  Project: Fundamental

  • Connexins 100%
  • Gap Junctions 62%
  • Cell Death 37%
  • Liver 36%
  • Hepatic Stellate Cells 32%